Author Correction: A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control

Author Correction: A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8⁺ T-cell response and effective tumor control

Nat Commun. 2020 Apr 1;11(1):1716. doi: 10.1038/s41467-020-15532-1.

Zhichen Sun^{1

2}, Zhenhua Ren³, Kaiting Yang^{1

2}, Zhida Liu³, Shuaishuai Cao^{1

2}, Sisi Deng², Lily Xu⁴, Yong Liang¹, Jingya Guo^{1

2}, Yingjie Bian¹, Hairong Xu¹, Jiyun Shi⁵, Fan Wang^{5

6}, Yang-Xin Fu⁷, Hua Peng⁸

¹ Key Laboratory of Infection and Immunity of CAS, Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, China.
² University of Chinese Academy of Sciences, Beijing, 100049, China.
³ Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, 75235-9072, USA.
⁴ Department of Biological Sciences, University of Wellesley College, Wellesley, 02481 MA, USA.
⁵ Key Laboratory of Protein and Peptide Pharmaceuticals, CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, China.
⁶ Medical Isotopes Research Center and Department of Radiation Medicine, School of Basic Medical Sciences, Peking University, Beijing, China.
⁷ Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, 75235-9072, USA. yang-xin.fu@utsouthwestern.edu.
⁸ Key Laboratory of Infection and Immunity of CAS, Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, China. hpeng@moon.ibp.ac.cn.

An amendment to this paper has been published and can be accessed via a link at the top of the paper.